Although the schizophrenia drug market is crowded, few, if any, effective therapies are available in the United States and Europe to treat the disease’s negative symptoms (e.g., blunted affect, alogia). Of note, Allergan’s Vraylar has shown some efficacy in the treatment of predominant negative symptoms, and amisulpride is specifically approved in some European countries for the treatment of negative symptoms. Nevertheless, more therapies are needed. Given that a sizable proportion of schizophrenia patients exhibit negative symptoms, it is essential to understand how psychiatrists perceive the performance of current therapies and determine the greatest areas of unmet need and thus the opportunities in this space.


  • What is the relative importance of a therapy’s various attributes in psychiatrists’ prescribing decisions for the negative symptoms of schizophrenia (e.g., improvement of negative symptoms, improvement of patient functioning, improvement of positive symptoms)?
  • How do U.S. psychiatrists rate Vraylar as performing on key treatment drivers and goals for the negative symptoms of schizophrenia?
  • What are the prevailing areas of unmet need and opportunity in the treatment of the negative symptoms of schizophrenia?
  • What trade-offs across key drug attributes and price are acceptable to psychiatrists for a hypothetical new drug for the negative symptoms of schizophrenia?


Unmet Need: Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 psychiatrists in the United States and 33 psychiatrists in Europe.

Key companies: Allergan, Gedeon Richter, Recordati, Sanofi, Bristol-Myers Squibb, Janssen, Eli Lilly, Lundbeck, Otsuka Pharmaceuticals, Minerva Neurosciences.

Key drugs: Vraylar (U.S.)/Reagila (Europe), amisulpride (Europe), aripiprazole, risperidone, olanzapine, fluoxetine, citalopram, roluperidone (MIN-101).

Key metrics included:

  • Stated versus derived analysis of U.S. and European physician prescribing behavior.
  • Conjoint analysis with U.S. and European physicians, includes market simulator.
  • Assessment of current drug performance against treatment drivers and goals.
  • Physician perceptions of unmet need in disease/subpopulation covered and related diseases/subpopulations.
  • Analysis of remaining drug development opportunities.

Table of contents

  • Schizophrenia - Unmet Need - Detailed, Expanded Analysis (Negative Symptoms)

Author(s): Himanshu Jain, M.S. Pharm

Himanshu joined the CNS / ophthalmology team at Decision Resources Group in 2016. He has authored content for psychiatry and ophthalmology (retinal / nonretinal) indications, including schizophrenia, age-related macular degeneration, diabetic retinopathy / diabetic macular edema, dry eye disease, glaucoma, and uveitis.

Himanshu has more than ten years of experience working in market research and consulting firms, and has managed multiple market assessment projects, including bottom-up forecasts, across multiple therapy areas. He holds a M.S. degree in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research in India and an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.

Related Reports

Schizophrenia - Special Topics - Special Topics Evolving Market Dynamics In Schizophrenia US

The schizophrenia therapy market is dominated by oral and long-acting injectable (LAI) antipsychotics, which are primaril...

View Details

Schizophrenia - Special Topics - Special Topics: Agitation In Bipolar And Schizophrenia (US)

Agitation is a common behavioral aspect often associated with bipolar disorder (BPD) and schizophrenia. It often manifests in the form of tension, violence, or...

View Details

Schizophrenia - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)

Schizophrenia is an often disabling psychiatric disease that usually requires long-term treatment. The primary goals of medical treatment for schizophrenia are to reduce the frequency and severity...

View Details

Schizophrenia - Unmet Need - Detailed, Expanded Analysis (Cognitive Impairment)

Although the schizophrenia drug market is crowded, no pharmacological agents are approved specifically to treat cognitive impairment associated with schizophrenia (

View Details